Home The Word Brain My Amedeo FAQ Privacy About


Hanzi Hunter

Learning 500 Chinese characters in 30 days is possible.

Abstract • About

  Autoimmune Disorders

  Free Subscription


16.03.2026

2 Am J Kidney Dis
3 BMC Neurol
3 Brain
2 Curr Opin Immunol
8 Diabet Med
1 Diabetes
9 Diabetes Res Clin Pract
2 Intern Med
1 J Immunol
1 J Nephrol
8 J Neuroimmunol
16 J Neurol
7 J Pediatr Endocrinol Metab
1 J Rheumatol
2 Kidney Int
10 Mult Scler
2 N Engl J Med
1 Nat Rev Neurol
1 Neurol Clin Pract
2 Neurologia (Engl Ed)
4 Neurology
1 PLoS Biol
3 PLoS One
2 Proc Natl Acad Sci U S A
3 Thyroid


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Kidney Dis

  1. MORTON JI, Carstensen B, McDonald SP, Polkinghorne KR, et al
    Trends in the Incidence of End-Stage Kidney Disease in Type 1 and Type 2 Diabetes in Australia, 2010-2019.
    Am J Kidney Dis. 2023;82:608-616.
    PubMed         Abstract available

  2. REILY C, Novak J, Rizk DV
    The Roles of A Proliferation-Inducing Ligand (APRIL) and B-Cell Activating Factor (BAFF) in IgA Nephropathy.
    Am J Kidney Dis. 2026 Mar 5:S0272-6386(26)00729.
    PubMed         Abstract available


    BMC Neurol

  3. MACHADO A, Dervish J, Friberg E
    Employment status and self-rated health in people with multiple sclerosis in Sweden.
    BMC Neurol. 2026 Mar 11. doi: 10.1186/s12883-026-04809.
    PubMed        

  4. KIMBER C, Malouf R, Javan J, Doree C, et al
    Clinical and economic outcomes of therapeutic plasma exchange and intravenous immunoglobulin for treating adults with autoimmune neurological disorders: a systematic review and meta-analysis.
    BMC Neurol. 2026 Mar 7. doi: 10.1186/s12883-026-04780.
    PubMed        

  5. SHU J, Zhou Y, Xu Z, Wei W, et al
    MELAS syndrome complicated by anti-GFAP autoantibody positivity: a case report and literature review.
    BMC Neurol. 2026 Mar 7. doi: 10.1186/s12883-026-04745.
    PubMed        


    Brain

  6. CORAZZOLLA G, Treaba CA, Mohammadian M, Brusaferri L, et al
    Evidence of skull bone translocator protein overexpression linked to multiple sclerosis progression.
    Brain. 2026 Mar 9:awag084. doi: 10.1093.
    PubMed         Abstract available

  7. PAUL F
    Beyond autoantibodies: accelerating differential diagnosis in neuroimmunological diseases.
    Brain. 2026 Mar 11:awag093. doi: 10.1093.
    PubMed        

  8. YOGESHWAR SM, Bartels F, Gruter T, Muniz-Castrillo S, et al
    Brain atrophy patterns in anti-IgLON5 disease.
    Brain. 2026;149:884-896.
    PubMed         Abstract available


    Curr Opin Immunol

  9. GROSSI C, Buckle II, McDonnell TC
    Autoimmunity beyond antibodies: alternative roles of beta-2-glycoprotein I in and out of antiphospholipid syndrome?
    Curr Opin Immunol. 2026;100:102748.
    PubMed         Abstract available

  10. KIRINO Y, Takeno M
    A critical look at animal and cellular models in autoinflammatory diseases.
    Curr Opin Immunol. 2026;99:102719.
    PubMed         Abstract available


    Diabet Med

  11. MANSBRIDGE SE, Kozlowska O, Lumb A, Rea R, et al
    A multi-centre qualitative study of experiences of managing diabetes mellitus among adults while hospitalised.
    Diabet Med. 2026 Feb 18:e70256. doi: 10.1111/dme.70256.
    PubMed         Abstract available

  12. SANCHEZ-GARCIA D, Luna-Garza Y, Saavedra-Castillo E, Gomez-Martinez G, et al
    Effect of liraglutide on subclinical atherosclerosis and cardiometabolic risk factors in adults with type 1 diabetes: A prospective pilot study.
    Diabet Med. 2026 Feb 15:e70222. doi: 10.1111/dme.70222.
    PubMed         Abstract available

  13. SHACHAM EC, Sharif S, Tatoor R, Ayalon S, et al
    Prevalence and outcomes of DKA in type 1 and type 2 DM patients treated and not treated with SGLT-2 inhibitors.
    Diabet Med. 2026;43:e70237.
    PubMed         Abstract available

  14. HAGGER V, Hendrieckx C, Cotterill A, Speight J, et al
    Evaluation of a structured type 1 diabetes education program for adolescents and parents: Teens Empowered to Actively Manage Type 1 (TEAM T1).
    Diabet Med. 2026 Feb 5:e70244. doi: 10.1111/dme.70244.
    PubMed         Abstract available

  15. COOPER ZW, Davis GM, Pasquel FJ, Johnson LCM, et al
    Navigating the dual burden of type 1 diabetes and mental illness: A phenomenological study.
    Diabet Med. 2026 Feb 5:e70200. doi: 10.1111/dme.70200.
    PubMed         Abstract available

  16. SOHOLM U, Holmes-Truscott E, Amiel SA, de Galan B, et al
    Assessing thoughts, feelings and behaviours related to hypoglycaemia: Psychometric evaluation of the Hypoglycaemia Cues Questionnaire (HypoC-Q).
    Diabet Med. 2026;43:e70231.
    PubMed         Abstract available

  17. MECANI R, Muka T, Cigler M, Basta S, et al
    The use of diabetes technology under aviation conditions: A systematic review of human and in-vitro studies and future considerations.
    Diabet Med. 2026 Jan 23:e70220. doi: 10.1111/dme.70220.
    PubMed         Abstract available

  18. ZIEGLER J, Neu A, Ehehalt S, Schweizer R, et al
    Age-specific incidence and prevalence of childhood type 1 diabetes: Development over four decades in Southwest Germany.
    Diabet Med. 2026 Jan 6:e70215. doi: 10.1111/dme.70215.
    PubMed         Abstract available


    Diabetes

  19. THIRAWATANANOND P, Brown ME, Sachs LK, Arnoletti JM, et al
    Treg-Specific CD226 Deletion Reduces Diabetes Incidence in NOD Mice by Improving Regulatory T-Cell Stability.
    Diabetes. 2023;72:1629-1640.
    PubMed         Abstract available


    Diabetes Res Clin Pract

  20. MARLOW AL, King BR, Trost SG, Weaver N, et al
    Healthy weight and overweight adolescents with type 1 diabetes mellitus do not meet recommendations for daily physical activity and sleep.
    Diabetes Res Clin Pract. 2023;203:110879.
    PubMed         Abstract available

  21. JENKINS AJ, Carroll LM, Huang MLH, Wen-Loh Y, et al
    Mitochondrial DNA copy number in adults with and without Type 1 diabetes.
    Diabetes Res Clin Pract. 2023;203:110877.
    PubMed         Abstract available

  22. WANNES S, Gamal GM, Fredj MB, Al Qusayer D, et al
    Glucose control during Ramadan in a pediatric cohort with type 1 diabetes on MiniMed standard and advanced hybrid closed?loop systems: A pilot study.
    Diabetes Res Clin Pract. 2023;203:110867.
    PubMed         Abstract available

  23. SAJJADI SF, Sacre JW, Chen L, Wild SH, et al
    Algorithms to define diabetes type using data from administrative databases: A systematic review of the evidence.
    Diabetes Res Clin Pract. 2023;203:110859.
    PubMed         Abstract available

  24. POLICOLA C, Di Stasio E, Rizzi A, Foca F, et al
    Predisposition to eating disorders in adults with type 1 diabetes: Comparison between multiple daily injections and continuous subcutaneous insulin infusion.
    Diabetes Res Clin Pract. 2023;203:110882.
    PubMed         Abstract available

  25. WINTERDIJK P, Aanstoot HJ, Nefs G
    The impact of real-time sensor technology on quality of life for adults with type 1 diabetes: A Dutch national survey.
    Diabetes Res Clin Pract. 2023;203:110886.
    PubMed         Abstract available

  26. SEATON KM, Jones HC, Lee MH, Kilov G, et al
    Survey of glucose levels in adults with T1DM attending clinic using automated insulin delivery (AID) devices compared with manual insulin delivery.
    Diabetes Res Clin Pract. 2026;233:113136.
    PubMed         Abstract available

  27. QU HQ, Ostberg K, Slater DJ, Wang F, et al
    Sex specific genomic insights into type 1 diabetes through GWAS and single cell transcriptome analysis.
    Diabetes Res Clin Pract. 2026;234:113181.
    PubMed         Abstract available

  28. HEAGUE MO, Henney AE, Riley DR, Anson M, et al
    Long-term adverse multi-system health outcomes of gestational diabetes mellitus: an analysis of real-world cohort data.
    Diabetes Res Clin Pract. 2026;234:113171.
    PubMed         Abstract available


    Intern Med

  29. SAKURAI K, Ashikawa Y, Imaoka Y, Ohshima K, et al
    Adult T-cell Leukemia Following Satralizumab Treatment for Neuromyelitis Optica Spectrum Disorder.
    Intern Med. 2026;65:732-736.
    PubMed         Abstract available

  30. KUWAHARA Y, Nanri M, Kurihara Y, Tashiro H, et al
    Pulmonary Involvement in ANCA-associated Vasculitis Overlapping with Long-standing Systemic Lupus Erythematosus.
    Intern Med. 2026 Mar 10. doi: 10.2169/internalmedicine.6896.
    PubMed         Abstract available


    J Immunol

  31. CHEN J, Fu L, Gong Y, Liao L, et al
    IFNgamma/JAK/STAT1/CD38 pathway in SH2D1Bhigh NK cells: Implications for inflammation in type 1 diabetes.
    J Immunol. 2026;215:vkaf347.
    PubMed         Abstract available


    J Nephrol

  32. HUANG J, Xiao T, Zhang J, Li Y, et al
    Ambrisentan as adjunctive therapy for IgA nephropathy: a retrospective single-center analysis.
    J Nephrol. 2026 Feb 27:aajaf052. doi: 10.1093.
    PubMed         Abstract available


    J Neuroimmunol

  33. BENKHOUCHA M, Breville G, Senoner I, Chliate S, et al
    Soluble c-Met correlates with NfL and GFAP levels in the CSF of patients with multiple sclerosis.
    J Neuroimmunol. 2026;415:578895.
    PubMed        

  34. DAMSBO K, Reyahi A, Nik AM, Oubounyt M, et al
    Astrocyte-specific FoxF2 modulates immune and myelin repair: Evidence from multiple sclerosis lesions and an animal model.
    J Neuroimmunol. 2026;415:578896.
    PubMed         Abstract available

  35. ATASEVER U
    Bile acid-microbiota interactions in multiple sclerosis: From experimental models to early clinical evidence.
    J Neuroimmunol. 2026;415:578898.
    PubMed         Abstract available

  36. SARIN S, Modak N, Sun R, Subei O, et al
    Predicting the final clinical phenotype after the first attack of optic neuritis.
    J Neuroimmunol. 2023;381:578130.
    PubMed         Abstract available

  37. BLASK C, Schulze J, Rumpel S, Susse M, et al
    Modulation of cytokine release from peripheral blood mononuclear cells from multiple sclerosis patients by coenzyme A and soraphen A.
    J Neuroimmunol. 2023;381:578135.
    PubMed         Abstract available

  38. SANDWEISS AJ, Erickson TA, Jiang Y, Kannan V, et al
    Infectious profiles in pediatric anti-N-methyl-d-aspartate receptor encephalitis.
    J Neuroimmunol. 2023;381:578139.
    PubMed         Abstract available

  39. JAIN K, Anita M, Netravathi M
    Double hit - A case in point for dual seropositivity to AQP4 and MOG antibodies.
    J Neuroimmunol. 2023;383:578198.
    PubMed         Abstract available

  40. EVERS SMITH C, Scholz A, Zolno R, Gambrah-Lyles C, et al
    Safety and efficacy of intrathecal rituximab in refractory neuroimmune disorders- a case series.
    J Neuroimmunol. 2026;414:578890.
    PubMed         Abstract available


    J Neurol

  41. PETROU P, Achiron A, Cohen EG, Garty M, et al
    Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ Viewpoint.
    J Neurol. 2023 Jul 12. doi: 10.1007/s00415-023-11846.
    PubMed         Abstract available

  42. QIN M, Chen J, Guo X, Xiang X, et al
    Movement disorders in autoimmune encephalitis: an update.
    J Neurol. 2023;270:5288-5302.
    PubMed         Abstract available

  43. JAKIMOVSKI D, Zivadinov R, Weinstock Z, Fuchs TA, et al
    Cortical thickness and cognition in older people with multiple sclerosis.
    J Neurol. 2023 Aug 27. doi: 10.1007/s00415-023-11945.
    PubMed         Abstract available

  44. BONACCHI R, Valsasina P, Pagani E, Meani A, et al
    Sex-related differences in upper limb motor function in healthy subjects and multiple sclerosis patients: a multiparametric MRI study.
    J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11948.
    PubMed         Abstract available

  45. GENG C, Zhao W, Wang Z, Wu J, et al
    Acute necrotizing encephalopathy associated with COVID-19: case series and systematic review.
    J Neurol. 2023;270:5171-5181.
    PubMed         Abstract available

  46. OEZTUERK M, Huntemann N, Gerischer L, Herdick M, et al
    Early versus late add-on therapy in generalized myasthenia gravis: a multicenter real-world cohort study.
    J Neurol. 2026;273:168.
    PubMed         Abstract available

  47. BERGAMASCHI R, Ferraro OE, Enrico P, Marzia F, et al
    Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study.
    J Neurol. 2026;273:172.
    PubMed         Abstract available

  48. RICE C, Scolding N
    Primary central nervous system vasculitis: an update.
    J Neurol. 2026;273:179.
    PubMed         Abstract available

  49. KLOSTERMANN F, Steiner OL
    Non-sensorimotor symptoms in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2026;273:178.
    PubMed         Abstract available

  50. KLEIN KRANENBARG RAM, Blok KM, van Hasselt Y, Melisse S, et al
    Symptoms of depression and anxiety are early predictors of multi-domain disability progression in progressive MS.
    J Neurol. 2026;273:182.
    PubMed         Abstract available

  51. MIEGEL L, Hickstein J, Reibelt A, Heesen C, et al
    Myasthenia gravis and pregnancy: a systematic review and meta-analysis.
    J Neurol. 2026;273:184.
    PubMed         Abstract available

  52. MOLENAAR PCG, de Jong DJ, Hof SN, van Oirschot P, et al
    Digital monitoring of disease activity in relapsing-remitting multiple sclerosis.
    J Neurol. 2026;273:186.
    PubMed         Abstract available

  53. FREEDMAN DE, Benedict RHB, Oh J, Feinstein A, et al
    The non-linear relationship between self-reported cognitive concerns and performance-based cognitive dysfunction in people with multiple sclerosis: a cross-sectional study.
    J Neurol. 2026;273:190.
    PubMed         Abstract available

  54. CANDELORO R, Laudisi M, Ferri C, Baldi E, et al
    Beyond oligoclonal bands: the independent role of kappa free light chains in the diagnostic workup of multiple sclerosis.
    J Neurol. 2026;273:191.
    PubMed         Abstract available

  55. DIMITRIADOU EM, Tzanetakos D, Theodorou A, Akrivaki A, et al
    The predictive value of serum neurofilament light chain in achieving no evidence of disease activity-3 (NEDA-3) status in treatment-naive patients with multiple sclerosis.
    J Neurol. 2026;273:194.
    PubMed         Abstract available

  56. GUERRA T, Lucisano G, Rocca MA, Cocco E, et al
    HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMS.
    J Neurol. 2026;273:193.
    PubMed         Abstract available


    J Pediatr Endocrinol Metab

  57. MAINIERI F, Chiarelli F, Betterle C, Bernasconi S, et al
    Graves' disease after COVID mRNA vaccination for the first time diagnosed in adolescence-case report. Cause and effect relationship or simple coincidence?
    J Pediatr Endocrinol Metab. 2023;36:993-997.
    PubMed         Abstract available

  58. MUTLUER T, Aslan Genc H, Demir T, Demirel C, et al
    The effect of problem-solving skills on blood glucose regulation and disease management in children with type 1 diabetes mellitus.
    J Pediatr Endocrinol Metab. 2023;36:949-956.
    PubMed         Abstract available

  59. ODEH R, Gharaibeh L, Ibrahim S, Alassaf A, et al
    Associated autoimmune thyroid diseases in children and adolescents with type one diabetes in Jordan.
    J Pediatr Endocrinol Metab. 2023;36:917-924.
    PubMed         Abstract available

  60. ELHENAWY YI, Shaarawy MA, Selim EM
    Safety and efficacy of the structured onboarding steps and initiation protocol for MiniMed 780G system among an Egyptian cohort of young people living with type 1 diabetes.
    J Pediatr Endocrinol Metab. 2023;36:941-948.
    PubMed         Abstract available

  61. KARA A, Gercek HG, Ozkan Y, Celikkol Sadic C, et al
    Depression, anxiety, eating problems, and diabulimia risk in adolescents with type 1 diabetes: a case-control study.
    J Pediatr Endocrinol Metab. 2023;36:957-965.
    PubMed         Abstract available

  62. KOPRULU O, Karatas MC, Akbel S, Simsek FY, et al
    Impact of continuous glucose monitoring on fear of hypoglycemia and quality of life in children and adolescents with type 1 diabetes.
    J Pediatr Endocrinol Metab. 2026;39:258-264.
    PubMed         Abstract available

  63. POON SW, Chan KT, But BW, Wong SM, et al
    Suboptimal adoption of diabetes technology despite coverage and the impact on glycemic outcomes in children and adolescents with type 1 diabetes in Hong Kong.
    J Pediatr Endocrinol Metab. 2026;39:251-257.
    PubMed         Abstract available


    J Rheumatol

  64. CONCANNON HR, Sun K, Rogers JL, Clowse MEB, et al
    Differences in Self-Reported Medication Nonadherence and its Drivers in Young Adults versus Older Adults with Systemic Lupus Erythematosus.
    J Rheumatol. 2026 Mar 1:jrheum.2025-0602. doi: 10.3899/jrheum.2025-0602.
    PubMed         Abstract available


    Kidney Int

  65. AL JURDI A, Kotton CN, Lafayette R
    Modern challenges in infection prevention: encapsulated organisms in the era of novel complement inhibitors.
    Kidney Int. 2026;109:484-488.
    PubMed         Abstract available

  66. LEE M, Suzuki H, Ogiwara K, Aoki R, et al
    The nucleotide-sensing Toll-Like Receptor 9/Toll-Like Receptor 7 system is a potential therapeutic target for IgA nephropathy.
    Kidney Int. 2023;104:943-955.
    PubMed         Abstract available


    Mult Scler

  67. SPAGNOLO F, Gordaliza PM, Bhardwaj A, Lu PJ, et al
    A multi-modal deep learning network for the classification of paramagnetic rim and remyelinated lesions in multiple sclerosis.
    Mult Scler. 2026 Mar 6:13524585261421491. doi: 10.1177/13524585261421491.
    PubMed         Abstract available

  68. CORONA A, Clarelli F, Paakkonen K, Harroud A, et al
    Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.
    Mult Scler. 2026 Mar 3:13524585261417130. doi: 10.1177/13524585261417130.
    PubMed         Abstract available

  69. ABAD-INCHAURRONDO I, Lu S, Lui E, Susin-Calle S, et al
    Performance of the 2024 McDonald diagnostic criteria for multiple sclerosis.
    Mult Scler. 2026 Mar 3:13524585261421816. doi: 10.1177/13524585261421816.
    PubMed         Abstract available

  70. SIVA A, Kantarci O
    Multiple sclerosis controversies: Do MRI-negative relapses really exist? - Commentary.
    Mult Scler. 2026 Mar 3:13524585261423082. doi: 10.1177/13524585261423082.
    PubMed        

  71. EBRAHIMI A, Wiil UK, Olsson T, Lio P, et al
    A susceptibility network analysis of disease trajectories leading to multiple sclerosis: A nationwide cohort study.
    Mult Scler. 2026 Mar 10:13524585261421480. doi: 10.1177/13524585261421480.
    PubMed         Abstract available

  72. NOVA A, Di Caprio G, Gentilini D, Bernardinelli L, et al
    A bidirectional two-sample Mendelian randomization study of immune responses against Epstein-Barr virus nuclear antigen 1 and multiple sclerosis in individuals of European ancestry.
    Mult Scler. 2026 Mar 10:13524585261423063. doi: 10.1177/13524585261423063.
    PubMed         Abstract available

  73. INOJOSA H, Mathias R, Dillenseger A, Voigt I, et al
    AI-enabled Living Labs: Accelerating innovation in multiple sclerosis care and research.
    Mult Scler. 2026 Mar 13:13524585261424136. doi: 10.1177/13524585261424136.
    PubMed         Abstract available

  74. GRECO G, Delgado S, Francis A, Miron M, et al
    Predictive factors for immunosuppression-associated severe and opportunistic infections in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.
    Mult Scler. 2026;32:326-337.
    PubMed         Abstract available

  75. WENGER AL, Pagani E, Meani A, Preziosa P, et al
    Clinical and MRI substrates of Symbol Digit Modalities Test impairment in multiple sclerosis patients with an adult- and late-onset.
    Mult Scler. 2026 Feb 23:13524585261417265. doi: 10.1177/13524585261417265.
    PubMed         Abstract available

  76. FUJIHARA K, Isobe N, Miyamoto K, Niino M, et al
    Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).
    Mult Scler. 2026;32:302-314.
    PubMed         Abstract available


    N Engl J Med

  77. HEERSPINK HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, et al
    Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
    N Engl J Med. 2026;394:947-957.
    PubMed         Abstract available

  78. FURIE RA, Dall'Era M, Vital EM, Garg JP, et al
    Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus.
    N Engl J Med. 2026 Mar 6. doi: 10.1056/NEJMoa2516150.
    PubMed         Abstract available


    Nat Rev Neurol

  79. GRIMSEY B
    We need to talk about risk in multiple sclerosis.
    Nat Rev Neurol. 2026;22:137.
    PubMed        


    Neurol Clin Pract

  80. BOVE R, Simoni M, Castelo-Branco C, Correale J, et al
    Expert Opinion on Age-Related Sex Hormone Changes and Hypogonadism in People With Multiple Sclerosis: A Delphi Consensus Program.
    Neurol Clin Pract. 2026;16:e200588.
    PubMed         Abstract available


    Neurologia (Engl Ed)

  81. NAG A, Leon-Ruiz M, Bole K, Ghosh R, et al
    Alcoholic Wernicke's encephalopathy with cranial neuropathies, atypical neuroimaging, dry beriberi, and Graves' disease: A novel variant?
    Neurologia (Engl Ed). 2026;41:101892.
    PubMed        

  82. GHOSH R, Leon-Ruiz M, Bole K, Dubey S, et al
    Isolated bilateral facial palsy as the initial presenting manifestation of generalized myasthenia gravis preceding myasthenic crisis.
    Neurologia (Engl Ed). 2026;41:101894.
    PubMed        


    Neurology

  83. MARTINEZ SOSA S, Tisavipat N, Betting T, Guo Y, et al
    Pearls & Oy-sters: Using Susceptibility-Based Imaging in Highly Active Late-Onset Multiple Sclerosis.
    Neurology. 2026;106:e214794.
    PubMed         Abstract available

  84. SIRIRATNAM P, Jokubaitis VG, Van Der Walt A, Sanfilippo PG, et al
    Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2026;106:e214707.
    PubMed         Abstract available

  85. JACOBS BM, Schalk L, Tregaskis-Daniels E, Scalfari A, et al
    Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds.
    Neurology. 2026;106:e214708.
    PubMed         Abstract available

  86. KIM SH, Lee EJ, Lim YM, Kim H, et al
    Prevalence and Relative Proportions of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the Republic of Korea.
    Neurology. 2026;106:e214792.
    PubMed         Abstract available


    PLoS Biol

  87. JOHNSTONE JC, Mitchell R, Vyse TJ, Clarke AJ, et al
    The adaptor protein TASL is required for age-related B cell emergence and lupus-like disease development in mice.
    PLoS Biol. 2026;24:e3003342.
    PubMed         Abstract available


    PLoS One

  88. TAUFIQQURRACHMAN I, Witarto AP, Syam AF, Abdullah M, et al
    Diagnostic potential of total serum ghrelin in autoimmune gastritis: A systematic review and meta-analysis.
    PLoS One. 2026;21:e0344129.
    PubMed         Abstract available

  89. GIORDANO A, De Panfilis L, Zagarella RM, Di Domenico G, et al
    Communication competences of multiple sclerosis neurologists during advance care planning conversations: A multi-observer study.
    PLoS One. 2026;21:e0336183.
    PubMed         Abstract available

  90. LIANG C, Zhuo P, Zhang Y
    Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology.
    PLoS One. 2026;21:e0343084.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  91. LUM FM, Sattarnezhad N, Ho PP, Orr N, et al
    Multiple molecular mimics in Epstein Barr Nuclear Antigen-1, and the pathogenesis of multiple sclerosis.
    Proc Natl Acad Sci U S A. 2026;123:e2519445123.
    PubMed         Abstract available

  92. JANOVICOVA L, Janikova M, Pastorek M, Csizmadia E, et al
    Extracellular heme:DNA complexes promote oxidative stress and inflammation during lupus-associated hemolysis.
    Proc Natl Acad Sci U S A. 2026;123:e2526577123.
    PubMed         Abstract available


    Thyroid

  93. HAMADI D, Saad-Omer S, Toro-Tobon D, Stan MN, et al
    Beyond the Eyes: Is Teprotumumab Effective for Thyroid Dermopathy?
    Thyroid. 2026;36:213-218.
    PubMed         Abstract available

  94. KAHALY GJ, Wolf J, Luffy M, Albert K, et al
    Euthyroidism and Long-Term Remission of Graves' Hyperthyroidism Following Treatment With an FcRn Blocker: A Case Report.
    Thyroid. 2026 Feb 13:10507256261423190. doi: 10.1177/10507256261423190.
    PubMed         Abstract available

  95. TORO-TOBON D, Rachmasari K, Bradley E, Wagner L, et al
    Medical Therapy in Patients with Moderate to Severe, Steroid-resistant, Thyroid Eye Disease.
    Thyroid. 2023 Jul 29. doi: 10.1089/thy.2023.0167.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum